Dynorphin and prodynorphin mRNA changes in the striatum during nicotine withdrawal.
Nicotine withdrawal causes somatic and negative affective symptoms that contribute to relapse and continued tobacco smoking. So far, the neuronal substrates involved are not fully understood, and an opioid role has been suggested. In this regard, the opioid dynorphin (Dyn) is of interest as it produces aversive states and has been speculated to play a role in the nicotine behavioral syndrome. These studies explore whether Dyn metabolism is altered during withdrawal following chronic administration of nicotine. Mice were administered nicotine, 2 mg/kg, s.c., four times daily for 14 days, and Dyn and prodynorphin (PD) mRNA estimated in selective brain regions at various times (30 min to 96 h) following drug discontinuation. The content of Dyn, estimated by RIA, was decreased in the striatum for a protracted time, from 30 min to over 72 h. In contrast, the mRNA for PD, evaluated by Northern blot, was elevated, appearing by 8 h and lasting over 96 h. Dyn was decreased in both ventral and dorsal striatum, and PD mRNA was differentially increased in the two striatal compartments as demonstrated by in situ hybridization. PD message was predominantly augmented in the nucleus accumbens, rostral pole, core, and shell, and the medial aspects of caudate/putamen. We interpret these data to indicate increased activity of striatal, particularly accumbal, dynorphinergic neurons during nicotine withdrawal resulting in enhanced peptide release and compensatory synthesis. Heightened dynorphinergic tone might be responsible, in part, for the emergence of the negative affective states observed during nicotine withdrawal.
Isola
Raffaella
R
Department of Psychiatry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA.
Zhang
Hailing
H
Tejwani
Gopi A
GA
Neff
Norton H
NH
Hadjiconstantinou
Maria
M
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D001931:Brain Mapping; D003342:Corpus Striatum / Q000378:metabolism*; D004334:Drug Administration Schedule; D004399:Dynorphins / Q000235:genetics* / Q000378:metabolism; D004745:Enkephalins / Q000235:genetics* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D051379:Mice; D009538:Nicotine / Q000009:adverse effects*; D011498:Protein Precursors / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D011863:Radioimmunoassay / Q000379:methods; D013375:Substance Withdrawal Syndrome / Q000473:pathology*; D013997:Time Factors
D004745:Enkephalins; D011498:Protein Precursors; D012333:RNA, Messenger; D009538:Nicotine; D004399:Dynorphins; C033660:preproenkephalin